scholarly journals Impact of an Intravenous Trimethoprim/Sulfamethoxazole Shortage on Treatment Outcomes Among HIV-Infected Patients with Pneumocystis jirovecii Pneumonia

2014 ◽  
Vol 20 (12) ◽  
pp. 1246-1254 ◽  
Author(s):  
Thomas J. Dilworth ◽  
Omar M. Ibrahim ◽  
Renée-Claude Mercier
Keyword(s):  
Treatment Outcomes ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia

scholarly journals Pneumocystis jirovecii Pneumonia Prophylaxis for Cancer Patients during Chemotherapy

Pathogens ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 237
Author(s):  
Kazuto Takeuchi ◽  
Yoshihiro Yakushijin
Keyword(s):  
Cancer Treatment ◽  
Treatment Outcomes ◽  
Cancer Patients ◽  
Potential Problem ◽  
Corticosteroid Treatment ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Immunocompromised Patients ◽  
Healthy Individuals ◽  
Life Threatening

Pneumocystis jirovecii pneumonia (PJP) is one type of life-threatening pneumonia in immunocompromised patients. PJP development should be considered in not only immunocompromised individuals, but also patients undergoing intensive chemotherapies and immunotherapies, organ transplantation, or corticosteroid treatment. Past studies have described the clinical manifestation of PJP in patients during chemotherapy and reported that PJP affects cancer treatment outcomes. Therefore, PJP could be a potential problem for the management of cancer patients during chemotherapy, and PJP prophylaxis would be important during cancer treatment. This review discusses PJ colonization in outpatients during cancer chemotherapy, as well as in healthy individuals, and provides an update on PJP prophylaxis for cancer patients during chemotherapy.

Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for Pneumocystis jirovecii pneumonia in pediatric oncology patients

2020 ◽  
pp. 107815522097904
Author(s):  
Monica Awad ◽  
Caroline M Sierra ◽  
Elhaam Mesghali ◽  
Khaled Bahjri
Keyword(s):  
Pediatric Oncology ◽  
Retrospective Cohort ◽  
Hematologic Malignancies ◽  
Primary Objective ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Weekly Dose ◽  
Single Center ◽  
Oncology Patients ◽  
Prophylaxis Therapy

Current recommendations for prophylaxis of Pneumocystis jirovecii pneumonia in oncology patients include administration of trimethoprim/sulfamethoxazole (TMP/SMX) three times weekly or the same total weekly dose given daily. The primary objective of this study was to evaluate the efficacy of two consecutive days per week of TMP/SMX for prevention of Pneumocystis jirovecii pneumonia (PJP) in pediatric oncology patients. A retrospective cohort, single-center analysis was conducted in oncology patients 21 years and younger who received TMP/SMX for PJP prophylaxis between February 1, 2013 and July 31, 2017. Changes to the prophylaxis regimen were documented and analyzed. A total of 322 patients received TMP/SMX on two consecutive days per week for PJP prevention, of whom four had confirmed PJP (1.3%). Neutropenia was the most common reason for switching to alternative prophylaxis therapy (11.5%). Two consecutive prophylaxis days with TMP/SMX may be insufficient to prevent PJP in children with hematologic malignancies. Neutropenia remains a barrier for TMP/SMX use for PJP prophylaxis. Further studies to compare PJP incidence in children receiving alternative prophylaxis regimens should be considered.

scholarly journals Pneumocystis and SARS-CoV-2 Co-Infection: A Case Report and Review of an Emerging Diagnostic Dilemma

2020 ◽  
Author(s):  
Carlos Rubiano ◽  
Kathleen Tompkins ◽  
Subhashini A Sellers ◽  
Brian Bramson ◽  
Joseph Eron ◽  
...  
Keyword(s):  
Case Report ◽  
Critically Ill ◽  
Therapeutic Strategies ◽  
Pneumocystis Jirovecii ◽  
Critically Ill Patient ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Diagnostic Dilemma

Abstract We present a case of a critically ill patient with COVID-19 found to have AIDS and Pneumocystis jirovecii pneumonia (PCP). COVID-19 and PCP co-occurrence is increasingly reported and may complicate diagnostic and therapeutic strategies. Patients with severe COVID-19 should be screened for underlying immunocompromise and coinfections should be considered.

scholarly journals COVID-19 and Pneumocystis jirovecii pneumonia: Back to the basics

2021 ◽  
Vol 79 ◽  
pp. 100814
Author(s):  
D. Mouren ◽  
C. Goyard ◽  
E. Catherinot ◽  
C. Givel ◽  
A. Chabrol ◽  
...  
Keyword(s):  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia
Sign in / Sign up

Export Citation Format

Share Document